Last reviewed · How we verify

Consolidation Chemotherapy

National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos · FDA-approved active Small molecule

Consolidation Chemotherapy is a Combination chemotherapy regimen Small molecule drug developed by National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos. It is currently FDA-approved for Acute leukemia (post-induction consolidation), Lymphoma (post-induction consolidation), Other hematologic malignancies requiring multi-phase chemotherapy. Also known as: XEOLX*4 courses, XELOX, CAPOX, CTX.

Consolidation chemotherapy uses a combination of cytotoxic agents to eliminate residual cancer cells remaining after initial treatment and reduce the risk of disease relapse.

Consolidation Chemotherapy is a treatment regimen used in the management of certain cancers, particularly after initial therapy to eliminate any remaining cancer cells and reduce the risk of recurrence. This approach is often employed in hematological malignancies such as acute myeloid leukemia (AML) and multiple myeloma. The regimen typically involves a combination of chemotherapeutic agents tailored to the specific type and stage of cancer. While there is no FDA label for this specific regimen, it is widely used in clinical practice and supported by various institutional guidelines. The treatment is associated with significant side effects, including myelosuppression, infections, and gastrointestinal symptoms, which require careful monitoring and management.

At a glance

Generic nameConsolidation Chemotherapy
Also known asXEOLX*4 courses, XELOX, CAPOX, CTX, Ara-C
SponsorNational Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Drug classCombination chemotherapy regimen
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Consolidation chemotherapy is administered after initial induction therapy to target any remaining malignant cells that may not have been eliminated by the first treatment phase. By using multiple cytotoxic agents with different mechanisms of action, this approach aims to maximize cell kill across heterogeneous cancer populations and improve long-term disease-free survival. The regimen is tailored based on cancer type, patient response to induction therapy, and individual tolerability factors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Consolidation Chemotherapy

What is Consolidation Chemotherapy?

Consolidation Chemotherapy is a Combination chemotherapy regimen drug developed by National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos, indicated for Acute leukemia (post-induction consolidation), Lymphoma (post-induction consolidation), Other hematologic malignancies requiring multi-phase chemotherapy.

How does Consolidation Chemotherapy work?

Consolidation chemotherapy uses a combination of cytotoxic agents to eliminate residual cancer cells remaining after initial treatment and reduce the risk of disease relapse.

What is Consolidation Chemotherapy used for?

Consolidation Chemotherapy is indicated for Acute leukemia (post-induction consolidation), Lymphoma (post-induction consolidation), Other hematologic malignancies requiring multi-phase chemotherapy.

Who makes Consolidation Chemotherapy?

Consolidation Chemotherapy is developed and marketed by National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos (see full National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos pipeline at /company/national-cancer-center-affiliate-of-vilnius-university-hospital-santaros-kliniko).

Is Consolidation Chemotherapy also known as anything else?

Consolidation Chemotherapy is also known as XEOLX*4 courses, XELOX, CAPOX, CTX, Ara-C.

What drug class is Consolidation Chemotherapy in?

Consolidation Chemotherapy belongs to the Combination chemotherapy regimen class. See all Combination chemotherapy regimen drugs at /class/combination-chemotherapy-regimen.

What development phase is Consolidation Chemotherapy in?

Consolidation Chemotherapy is FDA-approved (marketed).

What are the side effects of Consolidation Chemotherapy?

Common side effects of Consolidation Chemotherapy include Myelosuppression (neutropenia, thrombocytopenia, anemia), Nausea and vomiting, Mucositis, Infection, Hepatotoxicity, Nephrotoxicity.

Related